

In the claims:

1-32. (cancelled)

33. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 2A (SEQ ID NO:7) or a mature form thereof.

34. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or a mature form thereof.

35. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) or a mature form thereof.

36. (previously presented) An antibody or fragment thereof which specifically binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

37. (previously presented) An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) and to a mature form of a B7RP1 polypeptide as set forth in Figure 2A (SEQ ID NO:7).

38. (**currently amended**) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a B7RP1 polypeptide or as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. (**currently amended**) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a B7RP1 polypeptide or as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. (**currently amended**) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, or fragment thereof, of a B7RP1 polypeptide or as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

41. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. (currently amended) The antibody or fragment of Claims 34, 35, 36 or 37 which is an agonist antibody that increases B7RP-1 mediated immune T cell costimulatory activity.

43. (currently amended) The antibody or fragment of Claims 34, 35, 36 or 37 which is an antagonist antibody that decreases B7RP-1 mediated immune T cell costimulatory activity.

44. (currently amended) The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits B7RP-1 mediated immune T cell costimulatory activity.

45. (previously presented) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. (previously presented) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. (currently amended) An antibody or fragment which binds to a soluble form of B7RP1, wherein B7RP1 is encoded by the nucleic acid of as set forth in Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.

52. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.

53. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a human antibody.

54. (previously presented) A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.